Leveraging TROP2 Antibody-Drug Conjugates in Solid Tumors.

Citations in the corpus

TROP2 expression in head and neck squamous cell carcinoma: association with the tumor immune microenvironment and clinical outcome (2026, unknown): “…that persist across disease stages are essential for the effective development of antibody-based therapies, including monoclonal antibodies and antibody – drug conjugates (ADCs) as it is already an important therapeutic target in various solid tumors as lung cancer and breast cancer (17, 36 – 38).”